The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey
Abstract
Purpose: As chemotherapy costs escalate, financial concerns have become relevant for more cancer patients. Yet, little is known about how oncologists communicate with patients about coping with chemotherapy treatment costs. Methods: To understand how medical oncologists view these issues, we developed a survey eliciting their attitudes and behaviors surrounding discussing costs of therapy in the context of treatment decision making. The survey was piloted at a national meeting and then mailed to a random sample of actively practicing 2005 American Society of Clinical Oncology members in the 50 United States. Survey items used a 5-point Likert scale designed to elicit oncologists' practices and attitudes regarding discussion of chemotherapy costs with patients. The first survey wave also included two clinical vignettes about hypothetical patients contemplating treatment with high-cost regimens. Results: Of 530 mailed surveys, 167 were returned for an overall response rate of 31.5%. Most oncologists reported knowledge of their patients' financial well-being: 15% all of the time, 39% most of the time, 33% some of the time, and 13% rarely/none of the time. There was substantial variation in oncologists' attitudes toward discussing chemotherapy costs with patients: 42% did so always or most of the time, 32% sometimes did, and 26% rarely or never did. Most oncologists (80%) felt that it was important to be explicit about the impact of treatment choices on patients' finances. However, 20% maintained that costs play no role in clinical encounters, and 31% reported a high degree of discomfort in discussing costs with patients. Referral to support staff for these discussions was common. Only a few oncologists (16%) acknowledged omitting treatment options on the basis of their perceptions of patients' ability to afford treatment. Conclusion: There is important heterogeneity in medical oncologists' attitudes toward discussing chemotherapy treatment costs with patients. Mismatch between physician and patient viewpoints has the potential to result in miscommunication and suboptimally informed treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospect Theory: An Analysis of Decision under Risk
Kahneman, D., & Tversky, A. (1979) · Econometrica · doi:10.2307/1914185 · Cited by 48,524
Cited by
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Self-citationYabroff, K. R., Dowling, E. C., Guy, G. P., Banegas, M. P., Davidoff, A., Han, X., Virgo, K. S., McNeel, T. S., Chawla, N., Blanch-Hartigan, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0468 · Cited by 541
Financial Toxicity of Cancer Care: It’s Time to Intervene
Yousuf Zafar, S. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv370 · Cited by 536
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Jagsi, R., Pottow, J. A. E., Griffith, K. A., Bradley, C., Hamilton, A. S., Graff, J., Katz, S. J., & Hawley, S. T. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0956 · Cited by 277
Patient-Oncologist Cost Communication, Financial Distress, and Medication Adherence
Bestvina, C. M., Zullig, L. L., Rushing, C., Chino, F., Samsa, G. P., Altomare, I., Tulsky, J., Ubel, P., Schrag, D., Nicolla, J., et al. (2014) · Journal of Oncology Practice · doi:10.1200/jop.2014.001406 · Cited by 258
Self-citation
Metadata
- Authors
- Schrag, D., & Hanger, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-01-10
- Volume
- 25
- Issue
- 2
- Pages
- 233-237
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2039953424
- Cited by
- 194
- References
- 1
- FWCI
- 19.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.